Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price boosted by Royal Bank of Canada from $408.00 to $420.00 in a research report sent to investors on Tuesday morning,Benzinga ...

California-based bus manufacturer ENC has partnered with wireless EV charging pioneer InductEV to give transit operators a broader selection of electric bus options, including proven high-power ...

Omnicom and Interpublic today announced that each company's respective stockholders overwhelmingly approved Omnicom's previously announced acquisition of Interpublic at each company's Special Meeting ...

BGC Group Inc., a financial firm controlled by the billionaire Lutnick family, bought brokerage OTC Global Holdings for $325 ...

Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies.

The forward-looking statements contained in this Press Release are based on the expectations, estimates and projections of management of Vertex as of the date of this Press Release unless ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial.

Vertex Pharmaceuticals (VRTX) will release its next Annual Report on n/a. Vertex Pharmaceuticals's (VRTX) last annual report was released on n/a. DISCLOSURE: InvestSMART Group Limited employees may ...

BGC Group (NASDAQ:BGC), the financial brokerage firm once led by billionaire Howard Lutnick, has completed its previously announced acquisition of energy and commodities brokerage OTC Global ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...